

Multinational randomised controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritis

Submission date
09/05/2002

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
09/05/2002

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
15/11/2013

Condition category
Musculoskeletal Diseases

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Sean Curtis

Contact details

Merck & Co Inc
126 E Lincoln Avenue
Rahway
United States of America
NJ 07065

Additional identifiers

Protocol serial number

025

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Each site received the approval of its Ethics Review Committee or Institutional Review Board to perform the study.

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

1. Etoricoxib 90 mg once daily, naproxen 500 mg twice daily
2. Placebo for 12 weeks

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Etoricoxib, naproxen

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/06/2000

Eligibility

Key inclusion criteria

1. Patients with rheumatoid arthritis
2. Aged greater than or equal to 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

01/11/1999

Date of final enrolment

01/06/2000

Locations

Countries of recruitment

United Kingdom

Argentina

Australia

Austria

Brazil

Canada

Chile

Colombia

Costa Rica

France

Germany

Greece

Hong Kong

Israel

Italy

Lithuania

Mexico

New Zealand

Peru

Romania

Singapore

Slovenia

South Africa

Spain

Switzerland

Türkiye

United States of America

Venezuela

Study participating centre

Merck & Co Inc

Rahway

United States of America

NJ 07065

Sponsor information

Organisation

Merck & Co Inc (USA)

Funder(s)

Funder type

Industry

Funder Name

Merck & Co Inc (USA)

Alternative Name(s)

Merck & Co., Inc., Merck & Co.

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	22/05/2002		Yes	No